DK0587858T3 - Væksthormonholdig proteinformulering - Google Patents

Væksthormonholdig proteinformulering

Info

Publication number
DK0587858T3
DK0587858T3 DK93908252T DK93908252T DK0587858T3 DK 0587858 T3 DK0587858 T3 DK 0587858T3 DK 93908252 T DK93908252 T DK 93908252T DK 93908252 T DK93908252 T DK 93908252T DK 0587858 T3 DK0587858 T3 DK 0587858T3
Authority
DK
Denmark
Prior art keywords
growth hormone
pct
formulation
citrate
buffer substance
Prior art date
Application number
DK93908252T
Other languages
English (en)
Inventor
Staffan Castensson
Ebba Florin-Robertsson
Elvy Hoekby
Sirkka Thome
Original Assignee
Pharmacia & Upjohn Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=20385860&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK0587858(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Pharmacia & Upjohn Ab filed Critical Pharmacia & Upjohn Ab
Application granted granted Critical
Publication of DK0587858T3 publication Critical patent/DK0587858T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/27—Growth hormone [GH] (Somatotropin)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • General Chemical & Material Sciences (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Dermatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
DK93908252T 1992-04-03 1993-04-01 Væksthormonholdig proteinformulering DK0587858T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE9201073A SE9201073D0 (sv) 1992-04-03 1992-04-03 Protein formulation
PCT/SE1993/000281 WO1993019776A1 (en) 1992-04-03 1993-04-01 Protein formulation comprising growth hormone

Publications (1)

Publication Number Publication Date
DK0587858T3 true DK0587858T3 (da) 2000-12-18

Family

ID=20385860

Family Applications (1)

Application Number Title Priority Date Filing Date
DK93908252T DK0587858T3 (da) 1992-04-03 1993-04-01 Væksthormonholdig proteinformulering

Country Status (15)

Country Link
US (1) US5567677A (da)
EP (1) EP0587858B2 (da)
JP (1) JP3268557B2 (da)
AT (1) ATE196092T1 (da)
AU (1) AU666007B2 (da)
CA (1) CA2102693C (da)
DE (1) DE69329367T3 (da)
DK (1) DK0587858T3 (da)
ES (1) ES2150940T5 (da)
GR (1) GR3034925T3 (da)
NO (1) NO310804B1 (da)
NZ (1) NZ251498A (da)
PT (1) PT587858E (da)
SE (1) SE9201073D0 (da)
WO (1) WO1993019776A1 (da)

Families Citing this family (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5763394A (en) * 1988-04-15 1998-06-09 Genentech, Inc. Human growth hormone aqueous formulation
US5981485A (en) * 1997-07-14 1999-11-09 Genentech, Inc. Human growth hormone aqueous formulation
US5849704A (en) * 1991-12-20 1998-12-15 Novo Nordisk A/S Pharmaceutical formulation
US5849700A (en) * 1991-12-20 1998-12-15 Novo Nordisk A/S Pharmaceutical formulation
DK204791D0 (da) * 1991-12-20 1991-12-20 Novo Nordisk As Hidtil ukendt farmaceutisk praeparat
US6022858A (en) * 1991-12-20 2000-02-08 Novo Nordisk A/S Pharmaceutical formulation of human-growth hormone pretreated with zinc salt
FR2686899B1 (fr) 1992-01-31 1995-09-01 Rhone Poulenc Rorer Sa Nouveaux polypeptides biologiquement actifs, leur preparation et compositions pharmaceutiques les contenant.
FR2719479B1 (fr) * 1994-05-04 1996-07-26 Sanofi Elf Formulation stable lyophilisée comprenant une protéine: kit de dosage.
US5654278A (en) * 1994-10-13 1997-08-05 Novo Nordisk A/S Composition and method comprising growth hormone and leucine
US5631225A (en) * 1994-10-13 1997-05-20 Novo Nordisk A/S Pharmaceutical formulation
IL115592A (en) * 1994-10-13 2000-07-26 Novo Nordisk As Stabilized pharmaceutical formulation comprising a growth hormone and leucine
US5547696A (en) * 1994-10-13 1996-08-20 Novo Nordisk A/S Pharmaceutical formulation
US5705482A (en) * 1995-01-13 1998-01-06 Novo Nordisk A/S Pharmaceutical formulation
US5552385A (en) * 1995-06-05 1996-09-03 Novo Nordisk A/S Pharmaceutical formulation
DE19539574A1 (de) 1995-10-25 1997-04-30 Boehringer Mannheim Gmbh Zubereitungen und Verfahren zur Stabilisierung biologischer Materialien mittels Trocknungsverfahren ohne Einfrieren
GB9526733D0 (en) * 1995-12-30 1996-02-28 Delta Biotechnology Ltd Fusion proteins
AUPN801296A0 (en) 1996-02-12 1996-03-07 Csl Limited Stabilised growth hormone formulation and method of preparation thereof
US20070179096A1 (en) 1996-04-24 2007-08-02 Novo Nordisk A/S Pharmaceutical Formulation
ZA9711731B (en) * 1996-12-31 1998-07-01 Monsanto Co Aqueous glycerol formulations of somatotropin
ZA9711733B (en) 1996-12-31 1998-07-01 Monsanto Co Method for solubilization and naturation of somatotropins
JP3723857B2 (ja) * 1998-02-04 2005-12-07 日本ケミカルリサーチ株式会社 ヒト成長ホルモン含有水性医薬組成物
US6979442B1 (en) 1998-08-17 2005-12-27 Pfizer Inc. Stabilized protein compositions
JP2003504346A (ja) * 1999-07-12 2003-02-04 グランデイス・バイオテツク・ゲー・エム・ベー・ハー 成長ホルモン製剤
EP1309312A2 (en) * 2000-08-07 2003-05-14 Inhale Therapeutic Systems, Inc. Inhaleable spray dried 4-helix bundle protein powders having minimized aggregation
GB2371227A (en) * 2001-01-10 2002-07-24 Grandis Biotech Gmbh Crystallisation - resistant aqueous growth hormone formulations
WO2002092619A2 (en) * 2001-05-14 2002-11-21 The Gouvernment Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services Modified growth hormone
AU2002364587A1 (en) 2001-12-21 2003-07-30 Human Genome Sciences, Inc. Albumin fusion proteins
CA2475953A1 (en) * 2002-02-27 2003-09-04 E. Ann Tallant Angiotensin-(1-7) and angiotensin-(1-7) agonists for inhibition of cancer cell growth
AR040526A1 (es) * 2002-07-09 2005-04-13 Grandis Biotech Gmbh Formulaciuones de hgh en alta concentracion que contienen fenol
US20070065469A1 (en) * 2002-07-09 2007-03-22 Michael Betz Liquid formulations with high concentration of human growth hormone (high) comprising glycine
WO2004082707A2 (en) * 2003-03-18 2004-09-30 Ares Trading Sa Stabilisation of growth hormones in solution
ES2383691T3 (es) 2003-12-23 2012-06-25 Pharmacia Corporation Formulación líquida estable de hormonas de crecimiento
CA2559918A1 (en) * 2004-04-07 2005-11-10 Tudor Arvinte Liquid growth hormone formulation
EP1776459A1 (en) * 2004-08-03 2007-04-25 Transtech Pharma, Inc. Rage fusion proteins and methods of use
WO2006017647A1 (en) * 2004-08-03 2006-02-16 Transtech Pharma, Inc. Rage fusion proteins and methods of use
CA2576473C (en) * 2004-08-24 2015-06-30 Daiichi Asubio Pharma Co., Ltd. Liquid preparation of physiologically active peptide
PT1809663E (pt) * 2004-11-09 2008-10-02 Ares Trading Sa Um cesto para cultivo de marisco
US20070015689A1 (en) * 2005-06-23 2007-01-18 Alza Corporation Complexation of metal ions with polypeptides
EP1917276B1 (en) * 2005-08-26 2018-03-21 Ares Trading S.A. Process for the preparation of glycosylated interferon beta
EP1948221B1 (en) * 2005-11-02 2015-04-08 Syneron Medical Ltd. Human growth hormone patch formulations
AU2006323925B2 (en) * 2005-12-09 2012-08-02 Ares Trading S.A. Method for purifying FSH or a FSH mutant
JP5314428B2 (ja) * 2005-12-23 2013-10-16 ジーコデール システムズ アクチボラゲット 測位用パターン
AU2007215503A1 (en) * 2006-02-09 2007-08-23 Transtech Pharma, Inc. Rage fusion proteins and methods of use
EP2021474A2 (en) 2006-05-05 2009-02-11 Transtech Pharma, Inc. Rage fusion proteins, formulations, and methods of use thereof
WO2008100470A2 (en) * 2007-02-15 2008-08-21 Transtech Pharma, Inc. Rage - immunoglobulin fusion proteins
AU2008262490B2 (en) 2007-05-22 2011-11-17 Amgen Inc. Compositions and methods for producing bioactive fusion proteins
JP2011500757A (ja) * 2007-10-22 2011-01-06 メルク セローノ ソシエテ アノニム Ｆｃ含有タンパク質の精製方法
AU2008314687A1 (en) * 2007-10-22 2009-04-30 Merck Serono S.A. Method for purifying Fc-fusion proteins
RU2011142230A (ru) 2009-04-20 2013-05-27 Пфайзер Инк. Контроль гликозилирования белка и композиции и способы, касающиеся этого
EP2427215A1 (en) * 2009-05-07 2012-03-14 Novo Nordisk Health Care AG Stable pharmaceutical compositions of peptide derivatized using an oxime linker
AU2010321225B2 (en) * 2009-11-17 2015-12-03 Ipsen Pharma S.A.S. Formulation for hGH and rhIGF-1 combination
KR101337797B1 (ko) * 2010-07-14 2013-12-06 한미사이언스 주식회사 지속형 인간 성장 호르몬 결합체 액상 제제
US10064951B2 (en) 2012-03-30 2018-09-04 Hanmi Science Co., Ltd. Liquid formulation of highly concentrated long-acting human growth hormone conjugate
TW201605468A (zh) * 2013-09-27 2016-02-16 韓美藥品股份有限公司 長效人類生長激素接合物之製劑
JP6564369B2 (ja) 2013-12-09 2019-08-21 デュレクト コーポレイション 薬学的活性剤複合体、ポリマー複合体、ならびにこれらを伴う組成物及び方法
WO2016011281A1 (en) * 2014-07-17 2016-01-21 Teva Pharmaceutical Industries Ltd. FORMULATIONS OF AN ALBUMIN-hGH FUSION PROTEIN

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4783441A (en) * 1979-04-30 1988-11-08 Hoechst Aktiengesellschaft Aqueous protein solutions stable to denaturation
US4774091A (en) * 1983-10-14 1988-09-27 Sumitomo Pharmaceuticals Company, Ltd. Long-term sustained-release preparation
EP0189673B1 (en) * 1984-12-24 1990-09-26 Sumitomo Pharmaceuticals Company, Limited Stable growth hormone releasing factor preparation
PT83095B (en) * 1985-07-30 1987-12-23 Int Minerals & Chem Corp Method for the stabilization of growth promoting hormones using polyoxyethylene-polyoxypropylene copolymers
US4816568A (en) * 1986-05-16 1989-03-28 International Minerals & Chemical Corp. Stabilization of growth hormones
US4917685A (en) * 1986-05-16 1990-04-17 International Minerals & Chem. Corp. Delivery device for the administration of stabilized growth promoting hormones
ES2044941T5 (es) * 1987-08-21 1999-02-16 Mallinckrodt Group Inc Estabilizador de hormonas promotoras del crecimiento.
US4837202A (en) † 1987-09-14 1989-06-06 Pitman-Moore, Inc. Method for stimulating the immune system
US5096885A (en) * 1988-04-15 1992-03-17 Genentech, Inc. Human growth hormone formulation
JPH01308235A (ja) * 1988-06-03 1989-12-12 Yamanouchi Pharmaceut Co Ltd ヒト成長ホルモン経鼻剤
US5008244A (en) * 1989-05-15 1991-04-16 Pitman-Moore, Inc. Method for increasing fertility in animals
CA2020654A1 (en) * 1989-07-07 1991-01-08 Yohko Akiyama Stabilized fgf composition and production thereof
IN172427B (da) * 1989-11-14 1993-07-24 Fidia Spa
US5217954A (en) * 1990-04-04 1993-06-08 Scios Nova Inc. Formulations for stabilizing fibroblast growth factor
US5126324A (en) * 1990-06-07 1992-06-30 Genentech, Inc. Method of enhancing growth in patients using combination therapy
AU1757092A (en) * 1991-03-28 1992-11-02 Genentech Inc. Stable growth hormone metal ion formulations
DK204791D0 (da) * 1991-12-20 1991-12-20 Novo Nordisk As Hidtil ukendt farmaceutisk praeparat
AU679913B2 (en) † 1992-04-30 1997-07-17 Millennium Pharmaceuticals, Inc. Stable polypeptide composition
ATE359824T1 (de) * 1992-07-31 2007-05-15 Genentech Inc Wässrige formulierung enthaltend menschliches wachstumshormon

Also Published As

Publication number Publication date
CA2102693A1 (en) 1993-10-04
JPH06508156A (ja) 1994-09-14
PT587858E (pt) 2001-02-28
NO934355D0 (no) 1993-11-30
NO310804B1 (no) 2001-09-03
DE69329367T3 (de) 2008-06-19
DE69329367D1 (de) 2000-10-12
DE69329367T2 (de) 2001-06-21
ES2150940T3 (es) 2000-12-16
EP0587858B1 (en) 2000-09-06
EP0587858A1 (en) 1994-03-23
JP3268557B2 (ja) 2002-03-25
US5567677A (en) 1996-10-22
AU666007B2 (en) 1996-01-25
ES2150940T5 (es) 2008-04-16
SE9201073D0 (sv) 1992-04-03
NZ251498A (en) 1995-07-26
CA2102693C (en) 2008-06-17
ATE196092T1 (de) 2000-09-15
EP0587858B2 (en) 2007-11-14
NO934355L (no) 1993-12-01
AU3913593A (en) 1993-11-08
GR3034925T3 (en) 2001-02-28
WO1993019776A1 (en) 1993-10-14

Similar Documents

Publication Publication Date Title
DK0587858T3 (da) Væksthormonholdig proteinformulering
CA2275890A1 (en) Stable liquid interferon formulations
EP0747092A3 (en) Dissolution liquid for drug in iontophoresis
CN1281370A (zh) 稳定的特立帕肽溶液
IL135186A0 (en) LIQUID INTERFERON-β FORMULATIONS
DE59504750D1 (de) Verfahren zur gewinnung von hochreinem von willebrand-faktor
DK0910399T3 (da) Stabilt farmaceutisk BDNF-præparat
ATE326233T1 (de) Langfristig stabilisierte g-csf präparate
DE3585556D1 (de) Pharmazeutische zusammensetzungen, welche ein dipeptid enthalten.
ES2187820T3 (es) Formulaciones farmaceuticas de factor de liberacion de la corticotrop ina que tiene una estabilidad en su forma liquida.
Li Recent studies on the problems involved in the preparation, properties and bioassay of adrenocorticotrophic hormone
Holbrook et al. The identification of a peptide in human parotid saliva particularly active in enhancing the glycolytic activity of the salivary micro-organisms.
DK0641216T3 (da) Farmaceutisk præparat indeholdende IL-6
DK0873134T3 (da) Langvarig frigørelsesformulering omfattende bovin væksthormon frigørende faktor
Donohue Jr et al. Glucose-6-phosphate dehydrogenase Partial characterization of the rat liver and uterine enzymes
Leaver Studies on certain peptide fractions isolated from human dentine
ATE187077T1 (de) Wässrige zubereitung mit verzögerter wirkstofffreigabe
BR9006746A (pt) Peptideo fisiologicamente ativo e agente regulador do metabolismo de calcio